Receptor changes in metachronous breast tumors鈥攐ur experience of 10 years

详细信息	查看全文 | 推荐本文 |

• 作者：Jasneet Singh Bhullar ; M.D. ; M.S. ; ^{drjsbhullar@gmail.com} ; Amruta Unawane ; M.D. ; Gokulakkrishna Subhas ; M.D. ; M.R.C.S. ; Husein Poonawala ; M.D. ; Linda Dubay ; M.D. ; Lorenzo Ferguson ; M.D. ; Yousif Goriel ; M.D. ; Michael J. Jacobs ; M.D. ; Ramachandra B. Kolachalam ; M.D. ; Sumet Silapaswan ; M.D. ; Vijay K. Mittal ; M.D. ; F.A.C.S.
• 关键词：Metachronous breast cancer ; Synchronous breast cancer ; Estrogen ; Progesterone receptors ; Bilateral breast cancer
• 刊名：The American Journal of Surgery
• 出版年：2012
• 期刊代码：9_00029610
• 类别：med
• 出版时间：March, 2012
• 卷：203
• 期：3
• 页码：405-409
• 文件大小：283 K

摘要

Introduction

Patients with primary breast cancer (PBC) are at 2 to 6 times higher risk for developing synchronous and metachronous breast cancer (MBC). The pathology and behavior of MBC still remains unclear.

Methods

We reviewed the charts of 108 women with MBC at our hospital over the past 10 years. Profile patterns of the estrogen receptor (ER), the progesterone receptor (PR), and Her2/neu receptors were explored.

Results

Of 33 patients with ER⁺/PR⁺ in the primary tumor, 23 (70%) retained the status in MBC. Forty-five (92%) of 49 patients with ER^{鈭?/sup>/PR鈭?/sup> in the primary tumor remained the same in MBC. Most Her2鈭?/sup> tumors (22/31, 71%) remained negative, but 50%(8/16) of Her2+ tumors became negative.}

Conclusions

Most MBC retained the ER/PR expression patterns irrespective of the treatment for the primary tumor, thus suggesting a common origin. Because MBCs tend to be triple negative and thus more aggressive, early detection and close surveillance techniques must be devised.